Most peptides act on receptors on the surface of a cell. SS-31 does something rarer — it travels all the way inside, to the inner membrane of the mitochondria, and goes to work on the machinery that makes cellular energy. That is why it shows up in every serious conversation about mitochondrial health and aging. It is also a peptide with a real, large human trial behind it — and a result worth being honest about.
What SS-31 actually is
SS-31 — also known by its clinical name elamipretide, and sometimes MTP-131 — is a small, mitochondria-targeted tetrapeptide from the Szeto-Schiller family of compounds. Unlike most peptides, it is designed specifically to concentrate inside mitochondria, which is the whole basis of what it does.
How it works — the cardiolipin mechanism
SS-31 binds to cardiolipin, a unique lipid found on the inner mitochondrial membrane that is essential for the electron transport chain — the assembly line that produces ATP, the cell’s energy currency. In damaged or aging mitochondria, cardiolipin and that machinery degrade, energy output drops and reactive oxygen species (cellular “rust”) rise. By stabilising cardiolipin, SS-31 is proposed to improve the efficiency of energy production and reduce that oxidative damage. It is one of the more elegant mechanisms in the peptide world.
SS-31 is the rare peptide that made it into a large human trial. That is exactly why its honest result is more useful than any hype.TrueLabs Research Team
The human trials — the honest version
This is where SS-31 stands apart, and where most marketing goes quiet. As elamipretide, it was taken into real clinical trials — most notably MMPOWER-3, a randomised controlled trial in people with primary mitochondrial myopathy. The headline result: the trial did not meet its primary endpoint. Earlier, smaller data had looked promising, but the large confirmatory trial failed to show the benefit on its main measure.
That matters. A fascinating mechanism and strong early signals are not the same as proven efficacy — and SS-31 is a case study in the difference. Research into elamipretide for other conditions has continued, but the most rigorous test to date came up short on its primary goal.
So the honest summary is: a beautifully targeted mechanism, extensive preclinical support, a genuine human trial program, and a mixed-to-disappointing top-line clinical result. That is a more valuable thing to know than a list of benefits with no asterisks.
Where SS-31 fits
SS-31 belongs to the mitochondrial-and-longevity cluster researchers track together — alongside MOTS-c, NAD+ and epithalon. Each targets cellular aging from a different direction; SS-31’s angle is mitochondrial membrane integrity specifically. For the full landscape, see the peptides overview.
For a research setting, verify what you are studying: TrueLabs SS-31 ships with third-party purity data.
Researching mitochondrial peptides? Start with verified-purity material.
FAQ
What does SS-31 do?
It is a mitochondria-targeted peptide that binds cardiolipin, a lipid essential to the inner mitochondrial membrane and the energy-producing electron transport chain. By stabilising it, SS-31 is proposed to improve energy efficiency and reduce oxidative damage.
Is SS-31 the same as elamipretide?
Yes. SS-31 is the research name; elamipretide (also MTP-131) is the clinical name for the same molecule.
Did SS-31 work in human trials?
Its largest controlled trial, MMPOWER-3 in primary mitochondrial myopathy, did not meet its primary endpoint. Earlier smaller data looked promising, but the main confirmatory result fell short — an important caveat the hype often omits.
Is it an approved drug?
No. It has been studied clinically but is not an approved medicine, and is sold strictly for laboratory research use.
- Karaa A, et al. Efficacy and safety of elamipretide in primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology/JAMA, 2023. PMID 37268435.
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent. Br J Pharmacol. 2014.